NCT05878028View on ClinicalTrials.gov

L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

September 16, 2022

Primary Completion Date

September 15, 2025

Study Completion Date

September 15, 2025

Conditions
Non-small Cell Lung Cancer
Interventions
COMBINATION_PRODUCT

L-TIL, Tislelizumab, Docetaxel

PD1 positive lymphocytes were collect, isolated, and expanded from peripheral blood, then infused back into the patient's body. Besides this, Tislelizumab and Docetaxel were used as combination therapy.

Trial Locations (1)

450000

RECRUITING

No.127 Dongming Road, Zhengzhou

All Listed Sponsors
lead

Quanli Gao

OTHER_GOV